Nucleus Genomics raises $14M Series A to build next-gen consumer genomics platform
Jan 30, 2025
Key Points
- Nucleus Genomics raises $14M Series A led by Founders Fund and 776 to scale full-genome sequencing as a 23andMe alternative, posting 68% monthly revenue growth and 3x user expansion since November.
- Nucleus acquires Cambrian, an AI platform that transforms wearable data from Oura Ring and Apple Watch into health recommendations, signaling expansion beyond sequencing into integrated consumer health.
- Former Founders Fund chief of staff Matt Lanter joins as president while founder Sadeghi explores acquiring 23andMe itself, betting the category can consolidate under a consumer-first genomics leader.
Summary
Kian Sadeghi's Nucleus Genomics raised $14M in Series A funding with participation from Founders Fund, 776, Neo, Balaji Srinivasan, GiantStep VC, and 1818 Capital. The round closes on a company that has scaled dramatically in the past three months: 68% month-over-month revenue growth and 3x user growth since November. Less than a year after launch, Nucleus has moved from conducting 10 genetic analyses to over 800.
Nucleus positions itself as a next-generation alternative to 23andMe. Where 23andMe uses shotgun sequencing to reach roughly 90% coverage of a customer's genome, Nucleus delivers full-genome sequencing—the same technology labs use for rigorous scientific studies, now accessible to consumers through a direct-order kit. The company bundles this with AI-powered genetic risk assessments designed to surface preventable diseases rather than novelty ancestry data.
The timing capitalizes on erosion of trust in 23andMe. The company struggled as a business, faced potential takeover, and ownership uncertainty made consumers anxious about who controls their genetic data. Nucleus framed data portability as a selling point: customers can export their 23andMe data and request deletion from 23andMe's servers before any acquisition closes.
Broader moves signal ambition beyond sequencing. Nucleus acquired Cambrian, an AI-based health platform that transforms wearable data from devices like Oura Rings and Apple Watches into actionable recommendations. Founder David Sloan joins Nucleus's product team to lead wearable integrations. The company also sponsored a Jake Paul boxing match—a bet on reaching mainstream consumers rather than staying confined to tech circles, a calculated trade-off that leadership sees as necessary to scale a consumer health business into the billions.
Matt Lanter, former cofounder of Open Store and chief of staff at Founders Fund, joined as president. Lanter's decision to leave venture and investor optionality to join Nucleus signals founder quality; his statement cites "deep personal obsession with the problem" and "relentless drive" as the distinguishing qualities he'd seen only in the most successful founders.
Sadeghi has been public about expansion plans. In September 2024, he announced Nucleus was exploring an acquisition of 23andMe itself—contingent on financing and successful negotiation. While the move reads as exploratory, it signals intent to consolidate the consumer genomics category and access 23andMe's customer relationships and data. The acquisition would likely require over $100M even with debt.
Alexis Ohanian, a co-lead in the round, frames the broader opportunity: "The next $1 trillion business is going to be in consumer health. There's really no one else on the market building the way Kian and Nucleus are. Nucleus is running a playbook in health care that used to belong only to purely software companies."